Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 234

1.

Repeat vaccination reduces antibody affinity maturation across different influenza vaccine platforms in humans.

Khurana S, Hahn M, Coyle EM, King LR, Lin TL, Treanor J, Sant A, Golding H.

Nat Commun. 2019 Jul 26;10(1):3338. doi: 10.1038/s41467-019-11296-5.

2.

Prevalence of gestational diabetes mellitus among women attending antenatal care at public health centers in Rwanda.

Meharry PM, Tengera O, Rulisa S, Byambu AK, Nietert PJ, Byiringiro S, Habimana C, Gishoma C, King LR.

Diabetes Res Clin Pract. 2019 May;151:252-259. doi: 10.1016/j.diabres.2019.03.035. Epub 2019 Apr 1.

PMID:
30946850
3.

AS03-adjuvanted H5N1 vaccine promotes antibody diversity and affinity maturation, NAI titers, cross-clade H5N1 neutralization, but not H1N1 cross-subtype neutralization.

Khurana S, Coyle EM, Manischewitz J, King LR, Gao J, Germain RN, Schwartzberg PL, Tsang JS, Golding H; and the CHI Consortium.

NPJ Vaccines. 2018 Oct 1;3:40. doi: 10.1038/s41541-018-0076-2. eCollection 2018.

4.

Are Public Health Academia, Professional Certification, and Public Health Practice on the Same Page?

Foster A, King LR, Bender K.

J Public Health Manag Pract. 2018 May/Jun;24 Suppl 3:S47-S50. doi: 10.1097/PHH.0000000000000746. No abstract available.

PMID:
29595598
5.

A Potent Germline-like Human Monoclonal Antibody Targets a pH-Sensitive Epitope on H7N9 Influenza Hemagglutinin.

Yu F, Song H, Wu Y, Chang SY, Wang L, Li W, Hong B, Xia S, Wang C, Khurana S, Feng Y, Wang Y, Sun Z, He B, Hou D, Manischewitz J, King LR, Song Y, Min JY, Golding H, Ji X, Lu L, Jiang S, Dimitrov DS, Ying T.

Cell Host Microbe. 2017 Oct 11;22(4):471-483.e5. doi: 10.1016/j.chom.2017.08.011. Epub 2017 Sep 28.

6.

Patients with MS under daclizumab therapy mount normal immune responses to influenza vaccination.

Lin YC, Winokur P, Blake A, Wu T, Manischewitz J, King LR, Romm E, Golding H, Bielekova B.

Neurol Neuroimmunol Neuroinflamm. 2016 Jan 27;3(1):e196. doi: 10.1212/NXI.0000000000000196. eCollection 2016 Feb.

7.

ISCOMATRIX™ adjuvant promotes epitope spreading and antibody affinity maturation of influenza A H7N9 virus like particle vaccine that correlate with virus neutralization in humans.

Chung KY, Coyle EM, Jani D, King LR, Bhardwaj R, Fries L, Smith G, Glenn G, Golding H, Khurana S.

Vaccine. 2015 Jul 31;33(32):3953-62. doi: 10.1016/j.vaccine.2015.06.047. Epub 2015 Jun 17.

PMID:
26093202
8.

Whole grain in manufactured foods: Current use, challenges and the way forward.

Schaffer-Lequart C, Lehmann U, Ross AB, Roger O, Eldridge AL, Ananta E, Bietry MF, King LR, Moroni AV, Srichuwong S, Wavreille AS, Redgwell R, Labat E, Robin F.

Crit Rev Food Sci Nutr. 2017 May 24;57(8):1562-1568. doi: 10.1080/10408398.2013.781012. Review.

PMID:
25747755
9.

An interface to support independent use of Facebook by people with intellectual disability.

Davies DK, Stock SE, King LR, Brown RB, Wehmeyer ML, Shogren KA.

Intellect Dev Disabil. 2015 Feb;53(1):30-41. doi: 10.1352/1934-9556-53.1.30.

PMID:
25633380
10.

Oral priming with replicating adenovirus serotype 4 followed by subunit H5N1 vaccine boost promotes antibody affinity maturation and expands H5N1 cross-clade neutralization.

Khurana S, Coyle EM, Manischewitz J, King LR, Ishioka G, Alexander J, Smith J, Gurwith M, Golding H.

PLoS One. 2015 Jan 28;10(1):e0115476. doi: 10.1371/journal.pone.0115476. eCollection 2015.

11.

The evolution toward accreditation.

King LR, Petersen D.

Front Public Health. 2014 Nov 18;2:243. doi: 10.3389/fpubh.2014.00243. eCollection 2014. No abstract available.

12.

H5 N-terminal β sheet promotes oligomerization of H7-HA1 that induces better antibody affinity maturation and enhanced protection against H7N7 and H7N9 viruses compared to inactivated influenza vaccine.

Khurana S, Coyle EM, Verma S, King LR, Manischewitz J, Crevar CJ, Carter DM, Ross TM, Golding H.

Vaccine. 2014 Nov 12;32(48):6421-32. doi: 10.1016/j.vaccine.2014.09.049. Epub 2014 Oct 3.

PMID:
25284811
13.

Novel antibody-independent receptor-binding SPR-based assay for rapid measurement of influenza vaccine potency.

Khurana S, King LR, Manischewitz J, Coyle EM, Golding H.

Vaccine. 2014 Apr 17;32(19):2188-97. doi: 10.1016/j.vaccine.2014.02.049. Epub 2014 Mar 6.

PMID:
24613520
14.

A live attenuated influenza A(H5N1) vaccine induces long-term immunity in the absence of a primary antibody response.

Talaat KR, Luke CJ, Khurana S, Manischewitz J, King LR, McMahon BA, Karron RA, Lewis KD, Qin J, Follmann DA, Golding H, Neuzil KM, Subbarao K.

J Infect Dis. 2014 Jun 15;209(12):1860-9. doi: 10.1093/infdis/jiu123. Epub 2014 Mar 5. Erratum in: J Infect Dis. 2014 Dec 15;210(12):2021.

15.

Vaccine-induced anti-HA2 antibodies promote virus fusion and enhance influenza virus respiratory disease.

Khurana S, Loving CL, Manischewitz J, King LR, Gauger PC, Henningson J, Vincent AL, Golding H.

Sci Transl Med. 2013 Aug 28;5(200):200ra114. doi: 10.1126/scitranslmed.3006366.

16.

DNA priming prior to inactivated influenza A(H5N1) vaccination expands the antibody epitope repertoire and increases affinity maturation in a boost-interval-dependent manner in adults.

Khurana S, Wu J, Dimitrova M, King LR, Manischewitz J, Graham BS, Ledgerwood JE, Golding H.

J Infect Dis. 2013 Aug 1;208(3):413-7. doi: 10.1093/infdis/jit178. Epub 2013 Apr 30.

17.

Effects of postchallenge administration of ST-246 on dissemination of IHD-J-Luc vaccinia virus in normal mice and in immune-deficient mice reconstituted with T cells.

Zaitseva M, Shotwell E, Scott J, Cruz S, King LR, Manischewitz J, Diaz CG, Jordan RA, Grosenbach DW, Golding H.

J Virol. 2013 May;87(10):5564-76. doi: 10.1128/JVI.03426-12. Epub 2013 Mar 6.

18.

Preconfiguration of the antigen-binding site during affinity maturation of a broadly neutralizing influenza virus antibody.

Schmidt AG, Xu H, Khan AR, O'Donnell T, Khurana S, King LR, Manischewitz J, Golding H, Suphaphiphat P, Carfi A, Settembre EC, Dormitzer PR, Kepler TB, Zhang R, Moody MA, Haynes BF, Liao HX, Shaw DE, Harrison SC.

Proc Natl Acad Sci U S A. 2013 Jan 2;110(1):264-9. doi: 10.1073/pnas.1218256109. Epub 2012 Nov 21.

19.

Progress and directions in professional credentialing for health education in the United States.

Cottrell RR, Auld ME, Birch DA, Taub A, King LR, Allegrante JP.

Health Educ Behav. 2012 Dec;39(6):681-94. doi: 10.1177/1090198112466096. Epub 2012 Nov 21.

PMID:
23174628
20.

New developments in undergraduate education in public health: implications for health education and health promotion.

Barnes MD, Wykoff R, King LR, Petersen DJ.

Health Educ Behav. 2012 Dec;39(6):719-24. doi: 10.1177/1090198112464496. Epub 2012 Nov 7. Review.

PMID:
23136305
21.

Humans with chronic granulomatous disease maintain humoral immunologic memory despite low frequencies of circulating memory B cells.

Moir S, De Ravin SS, Santich BH, Kim JY, Posada JG, Ho J, Buckner CM, Wang W, Kardava L, Garofalo M, Marciano BE, Manischewitz J, King LR, Khurana S, Chun TW, Golding H, Fauci AS, Malech HL.

Blood. 2012 Dec 6;120(24):4850-8. doi: 10.1182/blood-2012-05-430959. Epub 2012 Oct 16.

22.

Hepatitis B assays in serum, plasma and whole blood on filter paper.

Mayer TK, Vargas RL, Knebel AE, Williams SA, Culver SP, Clark DM, King LR.

BMC Clin Pathol. 2012 May 20;12:8. doi: 10.1186/1472-6890-12-8.

23.

H5N1 virus-like particle vaccine elicits cross-reactive neutralizing antibodies that preferentially bind to the oligomeric form of influenza virus hemagglutinin in humans.

Khurana S, Wu J, Verma N, Verma S, Raghunandan R, Manischewitz J, King LR, Kpamegan E, Pincus S, Smith G, Glenn G, Golding H.

J Virol. 2011 Nov;85(21):10945-54. doi: 10.1128/JVI.05406-11. Epub 2011 Aug 24.

24.

Broadly neutralizing human antibody that recognizes the receptor-binding pocket of influenza virus hemagglutinin.

Whittle JR, Zhang R, Khurana S, King LR, Manischewitz J, Golding H, Dormitzer PR, Haynes BF, Walter EB, Moody MA, Kepler TB, Liao HX, Harrison SC.

Proc Natl Acad Sci U S A. 2011 Aug 23;108(34):14216-21. doi: 10.1073/pnas.1111497108. Epub 2011 Aug 8.

25.

Passive immunotherapies protect WRvFire and IHD-J-Luc vaccinia virus-infected mice from lethality by reducing viral loads in the upper respiratory tract and internal organs.

Zaitseva M, Kapnick SM, Meseda CA, Shotwell E, King LR, Manischewitz J, Scott J, Kodihalli S, Merchlinsky M, Nielsen H, Lantto J, Weir JP, Golding H.

J Virol. 2011 Sep;85(17):9147-58. doi: 10.1128/JVI.00121-11. Epub 2011 Jun 29.

26.

Recombinant HA1 produced in E. coli forms functional oligomers and generates strain-specific SRID potency antibodies for pandemic influenza vaccines.

Khurana S, Larkin C, Verma S, Joshi MB, Fontana J, Steven AC, King LR, Manischewitz J, McCormick W, Gupta RK, Golding H.

Vaccine. 2011 Aug 5;29(34):5657-65. doi: 10.1016/j.vaccine.2011.06.014. Epub 2011 Jun 23.

27.

Bacterial HA1 vaccine against pandemic H5N1 influenza virus: evidence of oligomerization, hemagglutination, and cross-protective immunity in ferrets.

Khurana S, Verma S, Verma N, Crevar CJ, Carter DM, Manischewitz J, King LR, Ross TM, Golding H.

J Virol. 2011 Feb;85(3):1246-56. doi: 10.1128/JVI.02107-10. Epub 2010 Nov 17.

28.

Properly folded bacterially expressed H1N1 hemagglutinin globular head and ectodomain vaccines protect ferrets against H1N1 pandemic influenza virus.

Khurana S, Verma S, Verma N, Crevar CJ, Carter DM, Manischewitz J, King LR, Ross TM, Golding H.

PLoS One. 2010 Jul 12;5(7):e11548. doi: 10.1371/journal.pone.0011548.

29.

Vaccines with MF59 adjuvant expand the antibody repertoire to target protective sites of pandemic avian H5N1 influenza virus.

Khurana S, Chearwae W, Castellino F, Manischewitz J, King LR, Honorkiewicz A, Rock MT, Edwards KM, Del Giudice G, Rappuoli R, Golding H.

Sci Transl Med. 2010 Jan 20;2(15):15ra5. doi: 10.1126/scitranslmed.3000624.

30.

Application of bioluminescence imaging to the prediction of lethality in vaccinia virus-infected mice.

Zaitseva M, Kapnick SM, Scott J, King LR, Manischewitz J, Sirota L, Kodihalli S, Golding H.

J Virol. 2009 Oct;83(20):10437-47. doi: 10.1128/JVI.01296-09. Epub 2009 Aug 5.

31.

Comparative evaluation of the immune responses and protection engendered by LC16m8 and Dryvax smallpox vaccines in a mouse model.

Meseda CA, Mayer AE, Kumar A, Garcia AD, Campbell J, Listrani P, Manischewitz J, King LR, Golding H, Merchlinsky M, Weir JP.

Clin Vaccine Immunol. 2009 Sep;16(9):1261-71. doi: 10.1128/CVI.00040-09. Epub 2009 Jul 15.

32.

Current developments in accreditation and certification for health promotion and health education: a perspective on systems of quality assurance in the United States.

Cottrell RR, Lysoby L, King LR, Airhihenbuwa CO, Roe KM, Allegrante JP.

Health Educ Behav. 2009 Jun;36(3):451-63. doi: 10.1177/1090198109333965. Epub 2009 May 15.

PMID:
19447945
33.

Antigenic fingerprinting of H5N1 avian influenza using convalescent sera and monoclonal antibodies reveals potential vaccine and diagnostic targets.

Khurana S, Suguitan AL Jr, Rivera Y, Simmons CP, Lanzavecchia A, Sallusto F, Manischewitz J, King LR, Subbarao K, Golding H.

PLoS Med. 2009 Apr 21;6(4):e1000049. doi: 10.1371/journal.pmed.1000049. Epub 2009 Apr 21.

34.

Electroporation of synthetic DNA antigens offers protection in nonhuman primates challenged with highly pathogenic avian influenza virus.

Laddy DJ, Yan J, Khan AS, Andersen H, Cohn A, Greenhouse J, Lewis M, Manischewitz J, King LR, Golding H, Draghia-Akli R, Weiner DB.

J Virol. 2009 May;83(9):4624-30. doi: 10.1128/JVI.02335-08. Epub 2009 Feb 11.

35.

"Moby-dick is my favorite:" evaluating a cognitively accessible portable reading system for audiobooks for individuals with intellectual disability.

Davies DK, Stock SE, King LR, Wehmeyer ML.

Intellect Dev Disabil. 2008 Aug;46(4):290-8. doi: 10.1352/1934-9556(2008)46[290:MIMFEA]2.0.CO;2.

PMID:
18671443
36.

Durable neutralizing antibodies after remote smallpox vaccination among adults with and without HIV infection.

Kan VL, Manischewitz J, King LR, Golding H.

AIDS. 2007 Feb 19;21(4):521-4.

PMID:
17301573
37.

Subunit recombinant vaccine protects against monkeypox.

Heraud JM, Edghill-Smith Y, Ayala V, Kalisz I, Parrino J, Kalyanaraman VS, Manischewitz J, King LR, Hryniewicz A, Trindade CJ, Hassett M, Tsai WP, Venzon D, Nalca A, Vaccari M, Silvera P, Bray M, Graham BS, Golding H, Hooper JW, Franchini G.

J Immunol. 2006 Aug 15;177(4):2552-64.

38.

Clinical and immunological comparison of smallpox vaccine administered to the outer versus the inner upper arms of vaccinia-naive adults.

Waibel KH, Golding H, Manischewitz J, King LR, Tuchscherer M, Topolski RL, Walsh DS.

Clin Infect Dis. 2006 Feb 15;42(4):e16-20. Epub 2006 Jan 10.

PMID:
16421781
39.

Enhanced immunogenicity and protective effect conferred by vaccination with combinations of modified vaccinia virus Ankara and licensed smallpox vaccine Dryvax in a mouse model.

Meseda CA, Garcia AD, Kumar A, Mayer AE, Manischewitz J, King LR, Golding H, Merchlinsky M, Weir JP.

Virology. 2005 Sep 1;339(2):164-75.

40.

CCR5 N-terminal region plays a critical role in HIV-1 inhibition by Toxoplasma gondii-derived cyclophilin-18.

Golding H, Khurana S, Yarovinsky F, King LR, Abdoulaeva G, Antonsson L, Owman C, Platt EJ, Kabat D, Andersen JF, Sher A.

J Biol Chem. 2005 Aug 19;280(33):29570-7. Epub 2005 Jun 23.

41.

Smallpox vaccine-induced antibodies are necessary and sufficient for protection against monkeypox virus.

Edghill-Smith Y, Golding H, Manischewitz J, King LR, Scott D, Bray M, Nalca A, Hooper JW, Whitehouse CA, Schmitz JE, Reimann KA, Franchini G.

Nat Med. 2005 Jul;11(7):740-7. Epub 2005 Jun 12.

PMID:
15951823
43.

Smallpox vaccine does not protect macaques with AIDS from a lethal monkeypox virus challenge.

Edghill-Smith Y, Bray M, Whitehouse CA, Miller D, Mucker E, Manischewitz J, King LR, Robert-Guroff M, Hryniewicz A, Venzon D, Meseda C, Weir J, Nalca A, Livingston V, Wells J, Lewis MG, Huggins J, Zwiers SH, Golding H, Franchini G.

J Infect Dis. 2005 Feb 1;191(3):372-81. Epub 2005 Jan 4.

PMID:
15633096
44.

Structural determinants of the anti-HIV activity of a CCR5 antagonist derived from Toxoplasma gondii.

Yarovinsky F, Andersen JF, King LR, Caspar P, Aliberti J, Golding H, Sher A.

J Biol Chem. 2004 Dec 17;279(51):53635-42. Epub 2004 Oct 6.

45.

Modeling a safer smallpox vaccination regimen, for human immunodeficiency virus type 1-infected patients, in immunocompromised macaques.

Edghill-Smith Y, Venzon D, Karpova T, McNally J, Nacsa J, Tsai WP, Tryniszewska E, Moniuszko M, Manischewitz J, King LR, Snodgrass SJ, Parrish J, Markham P, Sowers M, Martin D, Lewis MG, Berzofsky JA, Belyakov IM, Moss B, Tartaglia J, Bray M, Hirsch V, Golding H, Franchini G.

J Infect Dis. 2003 Oct 15;188(8):1181-91. Epub 2003 Oct 10.

PMID:
14551889
46.

The development of the management of vesico-ureteric reflux in the USA.

King LR.

BJU Int. 2003 Oct;92 Suppl 1:4-6. No abstract available.

48.

Development of a novel vaccinia-neutralization assay based on reporter-gene expression.

Manischewitz J, King LR, Bleckwenn NA, Shiloach J, Taffs R, Merchlinsky M, Eller N, Mikolajczyk MG, Clanton DJ, Monath T, Weltzin RA, Scott DE, Golding H.

J Infect Dis. 2003 Aug 1;188(3):440-8. Epub 2003 Jul 16.

PMID:
12870127
49.

Inhibition of HIV-1 infection by a CCR5-binding cyclophilin from Toxoplasma gondii.

Golding H, Aliberti J, King LR, Manischewitz J, Andersen J, Valenzuela J, Landau NR, Sher A.

Blood. 2003 Nov 1;102(9):3280-6. Epub 2003 Jul 10.

PMID:
12855560
50.

CXCR4 heterogeneity in primary cells: possible role of ubiquitination.

Lapham CK, Romantseva T, Petricoin E, King LR, Manischewitz J, Zaitseva MB, Golding H.

J Leukoc Biol. 2002 Dec;72(6):1206-14.

PMID:
12488503

Supplemental Content

Support Center